Literature DB >> 7876549

Induction of protective polyclonal antibodies by immunization with a Plasmodium yoelii circumsporozoite protein multiple antigen peptide vaccine.

R Wang1, Y Charoenvit, G Corradin, R Porrozzi, R L Hunter, G Glenn, C R Alving, P Church, S L Hoffman.   

Abstract

Monoclonal Abs against the repeat region of the circumsporozoite protein (CSP) completely protect mice against Plasmodium yoelii (Py), but synthetic peptide and recombinant protein vaccines designed to produce only Abs to the PyCSP repeat region have never been reported to consistently provide protection. This lack of protection in the rodent model system has predicted the poor protection achieved in humans after immunization with synthetic peptide and recombinant protein P. falciparum CSP vaccines and has raised serious questions regarding the capacity for vaccine-induced polyclonal Abs against the CSP to consistently protect humans. We now report immunization studies with a multiple Ag peptide vaccine designed to rely on "universal" T epitopes from tetanus toxin to produce T cell help for induction of protective Abs against the repeat region of the PyCSP. When delivered with a nonionic block co-polymer adjuvant, the vaccine protected 78 to 100% of three inbred strains of mice, and 100% of outbred mice against P. yoelii sporozoite challenge. Protection was associated with Ab titer, and passive transfer of purified IgG from immune mice protected naive recipients. Similar protection was achieved when the peptide was encapsulated in liposomes with lipid A and mixed with aluminum hydroxide. By demonstrating for the first time solid protection against P. yoelii by polyclonal Abs against the CSP, these data provide the rationale for assessment of a similarly constructed and formulated P. falciparum CSP multiple Ag peptide vaccine in humans.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7876549

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

1.  Infectivity of Plasmodium berghei sporozoites delivered by intravenous inoculation versus mosquito bite: implications for sporozoite vaccine trials.

Authors:  J A Vaughan; L F Scheller; R A Wirtz; A F Azad
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

2.  Immunogenicity of well-characterized synthetic Plasmodium falciparum multiple antigen peptide conjugates.

Authors:  M B Joshi; A A Gam; R A Boykins; S Kumar; J Sacci; S L Hoffman; H L Nakhasi; R T Kenney
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

3.  CD4(+) T-cell- and gamma interferon-dependent protection against murine malaria by immunization with linear synthetic peptides from a Plasmodium yoelii 17-kilodalton hepatocyte erythrocyte protein.

Authors:  Y Charoenvit; V F Majam; G Corradin; J B Sacci; R Wang; D L Doolan; T R Jones; E Abot; M E Patarroyo; F Guzman; S L Hoffman
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

4.  Replacing adenoviral vector HVR1 with a malaria B cell epitope improves immunogenicity and circumvents preexisting immunity to adenovirus in mice.

Authors:  Takayuki Shiratsuchi; Urvashi Rai; Anja Krause; Stefan Worgall; Moriya Tsuji
Journal:  J Clin Invest       Date:  2010-09-01       Impact factor: 14.808

5.  Development of two monoclonal antibodies against Plasmodium falciparum sporozoite surface protein 2 and mapping of B-cell epitopes.

Authors:  Y Charoenvit; V Fallarme; W O Rogers; J B Sacci; M Kaur; J C Aguiar; L F Yuan; G Corradin; E Andersen; B Wizel; R A Houghten; A Oloo; P De la Vega; S L Hoffman
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

6.  Adenovirus particles that display the Plasmodium falciparum circumsporozoite protein NANP repeat induce sporozoite-neutralizing antibodies in mice.

Authors:  Christopher Palma; Michael G Overstreet; Jean-Marc Guedon; Egbert Hoiczyk; Cameron Ward; Kasey A Karen; Fidel Zavala; Gary Ketner
Journal:  Vaccine       Date:  2011-01-01       Impact factor: 3.641

7.  A linear peptide containing minimal T- and B-cell epitopes of Plasmodium falciparum circumsporozoite protein elicits protection against transgenic sporozoite challenge.

Authors:  J Mauricio Calvo-Calle; Giane A Oliveira; Carol Othoro Watta; Jonathan Soverow; Carlos Parra-Lopez; Elizabeth H Nardin
Journal:  Infect Immun       Date:  2006-10-09       Impact factor: 3.441

8.  Why functional pre-erythrocytic and bloodstage malaria vaccines fail: a meta-analysis of fully protective immunizations and novel immunological model.

Authors:  D Lys Guilbride; Pawel Gawlinski; Patrick D L Guilbride
Journal:  PLoS One       Date:  2010-05-19       Impact factor: 3.240

Review 9.  The optimization of helper T lymphocyte (HTL) function in vaccine development.

Authors:  J Alexander; J Fikes; S Hoffman; E Franke; J Sacci; E Appella; F V Chisari; L G Guidotti; R W Chesnut; B Livingston; A Sette
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

10.  Antibodies to pre-erythrocytic Plasmodium falciparum antigens and risk of clinical malaria in Kenyan children.

Authors:  Chandy C John; Aaron J Tande; Ann M Moormann; Peter O Sumba; David E Lanar; Xinan M Min; James W Kazura
Journal:  J Infect Dis       Date:  2008-02-15       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.